Preclinical development of a chimeric tetravalent dengue vaccine

Information

  • Research Project
  • 7491487
  • ApplicationId
    7491487
  • Core Project Number
    U01AI070443
  • Full Project Number
    5U01AI070443-03
  • Serial Number
    70443
  • FOA Number
    RFA-AI-05-19
  • Sub Project Id
  • Project Start Date
    9/26/2006 - 18 years ago
  • Project End Date
    8/31/2010 - 14 years ago
  • Program Officer Name
    CASSETTI, CRISTINA
  • Budget Start Date
    9/1/2008 - 16 years ago
  • Budget End Date
    8/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/31/2008 - 16 years ago
Organizations

Preclinical development of a chimeric tetravalent dengue vaccine

[unreadable] DESCRIPTION (provided by applicant): Dengue virus is endemic throughout tropical regions of the world and threatens over half of the world's population. A vaccine that can protect against infection by all four of the dengue viruses (serotypes DEN-1 through DEN-4) is a critical global health need. The attenuated DEN-2 virus has been shown to be safe, potent and effective, generating long-lasting neutralizing antibody responses in human clinical trials. The mutations that weaken the virus have been characterized and lie outside the DEN-2 structural genes. The attenuated virus has been used as a backbone to express the structural genes of DEN-1, DEN-3 and DEN-4. Each "chimeric" virus bears the distinctive attenuation markers of the original DEN-2 parent and is safe and effective in animal models. Mixing the parent attenuated DEN-2 virus with the three chimeric viruses generates a tetravalent vaccine that can induce immune responses against all four dengue serotypes. We propose to complete the preclinical development of this unique vaccine. We will generate and characterize viral seed stocks required for manufacture of the vaccine. We will undertake formulation studies to optimize the activity of the vaccine. We will test the final, formulated vaccine in critical dengue models. We will develop both industry standard and unique assays to assure the safety, identity and potency of our vaccine. Finally, we will manufacture sufficient quantities of the vaccine to initiate human clinical trials. To achieve these goals, we have formed an international consortium of vaccine and dengue specialists from biotechnology, academia, and government institutions. To facilitate delivery of this vaccine to those that need it most, our unique collaboration includes an Indian manufacturer that globally supplies WHO-approved vaccines. Development of an affordable, safe and effective dengue vaccine will protect those that live in or travel to Asia, Central and South America, the Caribbean, the Pacific Islands, and parts of Africa and Australia. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    771968
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:771968\
  • Funding Mechanism
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INVIRAGEN, LLC
  • Organization Department
  • Organization DUNS
    141588801
  • Organization City
    FORT COLLINS
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80525
  • Organization District
    UNITED STATES